Literature DB >> 16804402

Functional consequences of NOD2 (CARD15) mutations.

Clara Abraham1, Judy H Cho.   

Abstract

Polymorphisms in NOD2 (CARD15) are associated with ileal and ileocolonic Crohn's disease, increased mortality from graft-versus-host disease, and Blau syndrome. NOD2 activation by peptidoglycan components initiates various signaling pathways and CD-associated NOD2 mutations are associated with decreased activation of NF-kappaB. NOD2 may be important for both initial defenses against commensal and pathogenic bacteria and tolerance mechanisms for maintaining controlled activation of the intestinal immune system. Significant progress has been made in defining NOD2 signaling partners and pathways and functional consequences of NOD2 mutations with respect to its activation, expression, signaling, synergistic effects with Toll-like receptor signaling, and antimicrobial effects. However, NOD2 contributions to human intestinal inflammation are complex and incompletely understood. Improved understanding of NOD2-mediated pathways may lead to identification of other molecules that can also contribute to the development of Crohn's disease in humans.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16804402     DOI: 10.1097/01.MIB.0000225332.83861.5f

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  44 in total

1.  A dual role for receptor-interacting protein kinase 2 (RIP2) kinase activity in nucleotide-binding oligomerization domain 2 (NOD2)-dependent autophagy.

Authors:  Craig R Homer; Amrita Kabi; Noemí Marina-García; Arun Sreekumar; Alexey I Nesvizhskii; Kourtney P Nickerson; Arul M Chinnaiyan; Gabriel Nuñez; Christine McDonald
Journal:  J Biol Chem       Date:  2012-06-04       Impact factor: 5.157

Review 2.  Inflammasome-mediated autoinflammatory disorders.

Authors:  Shruti P Wilson; Suzanne L Cassel
Journal:  Postgrad Med       Date:  2010-09       Impact factor: 3.840

3.  Distinct and overlapping genetic loci in Crohn's disease and ulcerative colitis: correlations with pathogenesis.

Authors:  Matti Waterman; Wei Xu; Joanne M Stempak; Raquel Milgrom; Charles N Bernstein; Anne M Griffiths; Gordon R Greenberg; A Hillary Steinhart; Mark S Silverberg
Journal:  Inflamm Bowel Dis       Date:  2010-12-10       Impact factor: 5.325

4.  Nucleotide-binding oligomerization domain (NOD) signaling defects and cell death susceptibility cannot be uncoupled in X-linked inhibitor of apoptosis (XIAP)-driven inflammatory disease.

Authors:  Steven M Chirieleison; Rebecca A Marsh; Prathna Kumar; Joseph K Rathkey; George R Dubyak; Derek W Abbott
Journal:  J Biol Chem       Date:  2017-04-12       Impact factor: 5.157

Review 5.  Human Melioidosis.

Authors:  I Gassiep; M Armstrong; R Norton
Journal:  Clin Microbiol Rev       Date:  2020-03-11       Impact factor: 26.132

6.  'Nodophagy': New crossroads in Crohn disease pathogenesis.

Authors:  Mahendrasingh Ramjeet; Séamus Hussey; Dana J Philpott; Leonardo H Travassos
Journal:  Gut Microbes       Date:  2010-08-08

7.  Altered cytokine profiles of mononuclear cells after stimulation in a patient with Blau syndrome.

Authors:  SangWook Son; JangHoon Lee; Chan-Wook Woo; IlHwan Kim; YoungChul Kye; KwangChul Lee; JungHwa Lee
Journal:  Rheumatol Int       Date:  2010-01-06       Impact factor: 2.631

Review 8.  Rheumatic manifestations in inflammatory bowel diseases: a link between GI and rheumatology.

Authors:  Rodolfo Perez-Alamino; Hernan Maldonado-Ficco; José A Maldonado-Cocco
Journal:  Clin Rheumatol       Date:  2015-11-17       Impact factor: 2.980

9.  Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes.

Authors:  D Santini; S Angeletti; A Ruzzo; G Dicuonzo; S Galluzzo; B Vincenzi; A Calvieri; F Pizzagalli; N Graziano; E Ferraro; G Lorino; A Altomare; M Magnani; F Graziano; G Tonini
Journal:  Clin Exp Immunol       Date:  2008-09-29       Impact factor: 4.330

10.  Long-term follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with chronically active inflammatory bowel disease.

Authors:  Annelie Lindberg; Michael Eberhardson; Mats Karlsson; Per Karlén
Journal:  BMC Gastroenterol       Date:  2010-07-06       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.